Key Points {#FPar1}
==========

In the treatment of hyperkalemia, the potassium adsorption ability of sodium polystyrene sulfonate (Na-resin) is slightly stronger than that of calcium polystyrene sulfonate (Ca-resin).Treatment with Na-resin is also expected to improve acidosis.Na-resin exhibits an advantage over Ca-resin because a smaller amount is sufficient to treat hyperkalemia (5--15 g/day); however, if a higher-dose ion-exchange resin is required, physicians should select the type and amount of resin according to the sodium and/or calcium load.

Introduction {#Sec1}
============

Hyperkalemia may cause fatal arrhythmia in patients undergoing maintenance hemodialysis. An overview of regular dialysis treatment in Japan found that, in 2013, of all deaths in Japanese patients receiving hemodialysis, 775 (2.6%) were attributable to hyperkalemia or sudden death \[[@CR1]\]. In the past 20 years, the rate of death due to hyperkalemia or sudden death was constant at 4.3 ± 0.8%. In the majority of patients receiving hemodialysis, it is possible to avoid death from hyperkalemia with dietary therapy and adequate hemodialysis. However, some patients require treatment with an ion-exchange resin to prevent hyperkalemia.

Although a promising new therapy for hyperkalemia has recently been developed, it is not yet available in Japan \[[@CR2], [@CR3]\]. Two types of ion-exchange resins are currently available in Japan for the treatment of hyperkalemia: sodium polystyrene sulfonate (Na-resin) was first sold in 1971, and calcium polystyrene sulfonate (Ca-resin) was released in 1975 to prevent the sodium loading caused by Na-resin and gradually became widespread as a treatment for hyperkalemia. However, we felt that serum K levels were insufficiently controlled with Ca-resin compared with Na-resin, and our patients had increasingly reported experiencing constipation. Upon returning to Na-resin, we were able to adjust serum K levels to lower values than previously.

Few papers have investigated the potassium adsorption ability of Ca-resin compared with that of Na-resin. Therefore, we investigated this issue among patients who switched from Ca-resin to an equivalent amount of Na-resin. Furthermore, in patients with oliguria or anuria receiving dialysis, the sodium load is expected to be reflected in an increase in sodium in the fluid, thus resulting in weight gain and increased blood pressure. Therefore, we also investigated the incidence of sodium loading in study participants, including those newly commencing Na-resin treatment.

Methods {#Sec2}
=======

This was a retrospective observational study. We included patients who switched from Ca-resin to an equivalent amount of Na-resin (change group) and patients who commenced treatment with Na-resin (new start group) between October 2009 and October 2012 at our own and affiliated hospitals. Patients received Na-resin after meals. In the change group, the time and frequency of taking the resins did not alter. Dialysis was performed at a blood flow rate of 200 ml/min and a dialysate potassium concentration of 2.0 mEq/l, which is a standard dialysis setting in Japan. We excluded patients whose dialysis conditions changed during the study period. At our hospital, all patients receive education on potassium-restricted diets when dialysis is introduced, but no additional education was given during this observation period. No other diet-related interventions were undertaken, nor were any changes made to the injected and oral medications before or after the start of Na-resin.

Patients were monitored for 4 weeks before and after the administration of Na-resin. Blood samples were collected before dialysis at the first session of each week. The parameters were compared by averaging four data points obtained over the 4-week period. The following parameters were measured: K, Na, Ca, Cl, P, estimated HCO~3~^−^ (eHCO~3~^−^ = Na -- Cl -- P − 7) \[[@CR4]\], blood pressure at the start of dialysis, weight gain (%) = (weight before hemodialysis − weight after hemodialysis at the last visit)/dry weight × 100, changes in medications (antihypertensive agents, laxative agents) and complaints of constipation. The serum Ca level was adjusted according to Payne's formula \[[@CR5]\]: serum Ca^+^ (4-serum Alb).

Continuous variables were assessed using Wilcoxon's signed-rank test with the Excel 2011 software package (Microsoft, Redmond, WA, USA) with the add-in software plugin Statcel 2 (OMS, Saitama, Japan). Dialysis conditions are presented as medians (minimum--maximum), and other data are presented as mean ± standard deviation. For all comparisons, differences at a *p* value \< 0.05 were considered statistically significant.

Results {#Sec3}
=======

Table [1](#Tab1){ref-type="table"} presents the background characteristics of enrolled patients (11 patients in the change group and 29 patients in the new start group).Table 1Patient characteristicsCharacteristicsChange groupNew start groupAge (years)^a^68.9 ± 12.066.3 ± 10.6Sex Male516 Female613Hemodialysis history (year)^b^6.8 ± 6.4 (2.6--25.2)7.0 ± 7.5 (0.2--31.9)Primary disease Chronic glomerulonephritis413 Diabetic nephropathy310 Nephrosclerosis12 Rapidly progressive glomerulonephritis01 Gout01 Pyelonephritis10 Unknown22Dialysis conditions Number of times per week33 Treatment time (h)^c^4.0 (4--4.5)4.0 (3.5--5.0) Quantity blood (ml/min)^c^200 (200--250)200 (200--200) Dialyzer  Membrane area (cm^2^)^c^1.9 (1--2.1)1.6 (1--2.1)  Membrane material   PS413   PES410   PEPA13   PMMA22  CTA1^a^Average ± standard deviation^b^Average ± standard deviation (minimum--maximum)^c^Median (minimum--maximum)*CTA* cellulose triacetate, *PES* polyethersulfone, *PEPA* polyester-based polymer alloy, *PMMA* polymethylmethacrylate, *PS* polysulfone

Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} show the data for the change group and the new start group, respectively. On average, the dose of resin was 8.2 ± 2.6 g/day in the change group and 8.7 ± 5.5 g/day in the new start group.Table 2Changes in parameters: change groupParameterCa-resinNa-resin*p* valueSBP (mmHg)152.4 ± 22.8152.2 ± 19.40.929DBP (mmHg)78.4 ± 13.783.4 ± 20.40.878∆Weight^a^ (%)4.7 ± 2.14.7 ± 1.90.859Na (mEq/l)138.1 ± 3.3138.6 ± 2.90.445K (mEq/l)5.5 ± 0.64.9 ± 0.6\<0.05Cl (mEq/l)104.4 ± 4.4102.6 ± 3.60.083Ca^b^ (mg/dl)9.1 ± 0.79.0 ± 0.60.139P (mg/dl)5.6 ± 0.76.5 ± 1.5\<0.05eHCO~3~^−c^ (mEq/l)21.1 ± 2.722.4 ± 3.0\<0.05All data presented as mean ± standard deviation*DBP* diastolic blood pressure, *SBP* systolic blood pressure^a^∆weight = \[(weight before hemodialysis − weight after last hemodialysis)/dry weight\] × 100^b^Ca adjusted by Payne's formula (adjusted Ca) = Ca + (4 − Alb)^c^Estimated HCO~3~^−^ = Na -- Cl -- P − 7 Table 3Changes in parameters: new start groupParameterNa-resin (−)Na-resin (+)*p* valueSBP (mmHg)145.8 ± 15.6145.5 ± 15.70.940DBP (mmHg)76.6 ± 8.278.4 ± 9.30.627∆Weight^a^ (%)5.0 ± 1.34.9 ± 1.10.381Na (mEq/l)137.4 ± 2.3139.0 ± 2.5\< 0.05K (mEq/l)5.9 ± 0.44.7 ± 0.6\< 0.05Cl (mEq/l)102.6 ± 2.7102.3 ± 3.00.430Ca^b^ (mg/dl)9.1 ± 0.79.0 ± 0.60.173P (mg/dl)6.3 ± 1.36.5 ± 1.20.186eHCO~3~^−\ c^ (mEq/l)21.5 ± 2.423.2 ± 2.3\< 0.05All dat presented as mean ± standard deviation^a^∆weight = \[(weight before hemodialysis − weight after last hemodialysis)/dry weight\] × 100^b^Ca adjusted by Payne's formula (adjusted Ca) = Ca^+^(4 − Alb)^c^Estimated HCO~3~^−^ = Na -- Cl -- P − 7

Serum K levels decreased significantly from 5.5 ± 0.6 to 4.9 ± 0.6 mEq/l in the change group and from 5.9 ± 0.4 to 4.7 ± 0.6 mEq/l in the new start group.

No changes were observed in blood pressure, weight gain or serum Na levels in the change group. Serum Na levels in the new start group increased significantly from 137.4 ± 2.3 to 139.0 ± 2.5 mEq/l, although they remained within the normal range. Antihypertensive agents were newly required in two cases in the new start group.

The rate at which constipation was reported and laxatives used did not change after switching from Ca-resin to Na-resin in the change group. Conversely, three patients in the new start group reported constipation but were able to continue taking Na-resin with the support of laxative agents. No patients reported being severely constipated.

Discussion {#Sec4}
==========

Two types of ion-exchange resins are available for the treatment of hyperkalemia in Japan: Na-resin and Ca-resin. There is a difference in cations between these agents. For example, in vitro examinations have shown that Na-resin 1000 mg exchanges bound Na for 110--135 mg of K, whereas Ca-resin 1000 mg exchanges bound Ca for 53--71 mg of K \[[@CR6]\]. Therefore, the amount of K adsorbed with Na-resin is expected to be twice that with Ca-resin. As shown in Fig. [1](#Fig1){ref-type="fig"} \[[@CR7]\], the difference in affinity of the cation to the polystyrene sulfonic acid resin is thought to be related to this phenomenon.Fig. 1Difference in affinity of the cation to the polystyrene sulfonic acid resin.Modified from The Japanese Pharmacopoeia \[[@CR7]\]

As to measurements of the ions adsorbed on the resin in the stool, only one report available of in vivo study and in English have demonstrated that Na-resin 1 g adsorbs an average of K 0.85 mEq, and Ca-resin 1 g adsorbs K 0.94 mEq \[[@CR8]\]. In practical terms, a significant decrease in serum K after switching from Ca-resin to Na-resin in patients in renal failure has been reported in the Japanese literature \[[@CR9]--[@CR11]\], but no reports are available in English. Our observation period was deliberately short to exclude the influence of factors other than resin. Serum K levels significantly decreased after switching from Ca-resin to the same amount of Na-resin. As such, we concluded that the K adsorption ability of Na-resin was stronger than that of Ca-resin.

As of 2012, Na-resin is available in 52 countries, whereas Ca-resin is available in only nine, primarily Asia, including Japan. Thus, reviews of these agents may be limited.

As to the effects of Na loading induced by Na-resin, the above-mentioned Japanese papers also reported \[[@CR9]--[@CR11]\] that serum Na levels increased from 0.58 to 2%, within the normal range, after switching from Ca-resin to Na-resin, although effects on body weight or blood pressure were not reported. Most patients receiving dialysis have oliguria or anuria. If the thirst center required to maintain homeostasis is functioning, the serum Na level is maintained within the normal range by drinking fluids, even in cases with Na loading. Therefore, in patients receiving dialysis, it is expected that the Na load would be reflected in increased weight gain and blood pressure relative to the serum Na concentration. However, we found no significant differences in either blood pressure or weight gain, although two patients in the new start group required additional medications for hypertension. If the antihypertensive medications had not been added, the changes in blood pressure would have been significant. At this time, the primary explanation for the lack of remarkable problems in fluid volume overload is that a relatively small amount of Na-resin was prescribed in this study. Nepal et al. \[[@CR12]\] reported the case of a female who developed hypernatremia in the setting of excessive Na-resin administration (60 g every 6 h). If more Na-resin had been administered in our cases, volume overload would have developed, leading to pulmonary edema. Therefore, when prescribing Na-resin, clinicians should be careful to prescribe an appropriate dose.

It has also been suggested that Na-resin is effective for not only hyperkalemia but also acidosis \[[@CR11]\]. In this study, we substituted eHCO~3~^−^ for HCO~3~^−^ values because HCO~3~^−^ was not often measured. The findings showed statistically significant improvements in acidosis, from 21.1 ± 2.7 to 22.4 ± 3.0 mEq/l in the change group and from 21.5 ± 2.4 to 23.2 ± 2.3 mEq/l in the new start group. Furthermore, it has been reported that the coronary artery calcification score is higher when the serum pre-dialysis HCO~3~^−^ value is low \[[@CR13]\]. Therefore, the effect of Na-resin in improving acidosis is considered useful.

We observed no changes in serum Ca levels after switching from Ca-resin to Na-resin and limited effects of Ca loading from Ca-resin. The primary explanation for the lack of change in serum Ca is that a relatively small amount of Ca-resin was prescribed in this study. An increased intake of Ca has also been reported to be a risk factor for vascular calcification and cardiovascular events \[[@CR14], [@CR15]\]. The clinical practice guidelines for chronic kidney disease-mineral and bone disorder (CKD--MBD) recommend that intake of precipitated calcium carbonate be limited to 3 g/day \[[@CR16]\] to prevent excessive Ca consumption. A total of Ca 350--450 mg is included in Ca-resin 5 g, whereas Ca 400 mg is included in CaCO~3~ 1 g; these values are almost equivalent. When prescribing Ca-resin and precipitated calcium carbonate simultaneously, physicians should be careful not to prescribe too much of either compound.

Two promising new drugs have recently been developed for the treatment of hyperkalemia. One reportedly contains calcium and is nonabsorbable \[[@CR2]\], the other contains sodium and has excellent adsorption power \[[@CR3]\], and both are expected to have few side effects. Practical clinical evaluations of these agents will be needed in the future.

Conclusion {#Sec5}
==========

When using an ion-exchange resin to treat hyperkalemia in patients with chronic renal failure, the K adsorption ability of Na-resin is slightly stronger than that of Ca-resin. In addition, treatment with Na-resin is expected to improve acidosis. When used in small amounts (5--15 g/day), as in the present study, Na-resin exhibits an advantage in the treatment of hyperkalemia. However, when prescribing a higher dose of ion-exchange resins, physicians should select the type and amount of resin according to the Na and/or Ca load in each case. As such, if \> 10 g of resins is needed to control hyperkalemia, combined Na-resin and Ca-resin may be necessary.
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